Article Text

PDF

Chloroquine as alternative antimalarial in systemic lupus erythematosus: response to ‘2019 update of the EULAR recommendations for the management of SLE: don’t forget chloroquine’ by Figueroa-Parra et al
  1. Antonis Fanouriakis1,
  2. George K Bertsias2,3,
  3. Dimitrios T Boumpas1,4,5
  1. 1Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece
  2. 2Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece
  3. 3Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, Heraklion, Greece
  4. 4Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
  5. 5Joint Academic Rheumatology Program, Medical School, National and Kapodestrian University of Athens, Athens, Greece
  1. Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Athens, 12462, Greece; afanour{at}med.uoa.gr

Statistics from Altmetric.com

We thank Drs Figueroa-Parra et al for their interest in our paper1 and their comment regarding the value of chloroquine (CQ) as an alternative antimalarial in systemic lupus erythematosus (SLE).2 As the authors point out, there are data, mostly for older studies, to support the efficacy of CQ in SLE.3 Nevertheless, over the last 20 years, hydroxychloroquine (HCQ) has largely displaced CQ in the USA and in Europe, mainly due to concerns for potential higher retinal toxicity of the latter (although no studies have formally tested different CQ doses in relation to toxicity).4 Accordingly, the vast majority of recent literature on the multiple benefits of antimalarial therapy refers to the use of HCQ,5 and there is general agreement that the latter should be the antimalarial of choice in SLE. Based on the above, the updated European League against Rheumatism recommendations for the management of lupus provide guidance reflecting current practice in the majority of settings and regions around the world. This being said, we acknowledge that in countries with significant cost differences between the two drugs, CQ may be considered as a justified alternative,6 with diligent monitoring for toxic retinopathy according to the recommendations.

References

View Abstract

Footnotes

  • Handling editor Josef S Smolen

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles